11 резултати
1. Current Knowledge and Rationale Gastro-esophageal (GE) cancers are a highly aggressive disease and are one of the major causes of cancer-related death in the world. Despite improvements in surgical and radiation techniques and the availability of newer agents, the prognosis of recurrent GE
This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab) in comparison to Herceptin® (Genentech/Roche) in patients with Human
Castration-resistant prostate cancer (CRPC) develops serial treatment resistance and is considered incurable. It is a largely indolent disease, which would give the body time to mount an effective immune response. CRPC is therefore potentially well suited for vaccine therapy.
Docetaxel is an
Castration-resistant prostate cancer (CRPC) develops serial treatment resistance and is considered incurable. It is a largely indolent disease, which would give the body time to mount an effective immune response. CRPC is therefore potentially well suited for vaccine therapy.
Sipuleucel-T
All subjects will have a baseline CT or FDG-PET/CT prior to initiation of therapy. This will be done at the Hillman or in Radiation Oncology. Enrolled patients will undergo appropriate lab work and staging as described
1. Albumin, alkaline phosphatase, glucose, electrolytes
2. Ca 19-9 and CEA
3. Due
1. Design: A randomized, controlled, open, parallel group study to assess the survival and disease-free period or progression in patients with advanced CGE over a period of 2 years.
2. Under study: Patients diagnosed in histology for the first time, advanced-stage CGE and fulfilling the inclusion
OBJECTIVES:
- To investigate the ability of selenium to prevent progression in patients with adenocarcinoma of the prostate.
- To investigate the ability of selenium to effectively modulate biomarkers of prostate cancer.
- To determine if selenium modifies the progression of prostate cancer based on
AIMS
The primary aim of the study is to test the hypothesis that tumour related disease free interval and overall survival are equivalent regardless whether patients receive laparoscopic colon resection (LCR) or open colon resection (OCR) at three and five years post operatively. The secondary aims
Objectives
Primary
- To assess the safety and tolerability of TroVax injections when given as a therapeutic vaccine to patients with metastatic renal cell cancer
- To assess the immune responses induced by treatment with TroVax
Secondary
- To assess the impact of treatment with TroVax on tumour
Objectives:
I. Compare the time to progression, time to development of disease-related pain, and incidence of grade 3 or worse treatment-related adverse events in patients with asymptomatic metastatic hormone refractory adenocarcinoma of the prostate treated with APC8015 versus control infusion. II.